the bulk lipid - regulating agent may be prepared by any available method , as for example the compound fenofibrate may be prepared by the procedure disclosed in u . s . pat . no . 4 , 058 , 552 , or the procedure disclosed in u . s . pat . no . 4 , 739 , 101 , both herein incorporated by reference . the composition comprising the lipid - regulating agent is prepared by dissolving or dispersing the lipid - regulating agent and hydrophilic , amorphous polymer in a sufficient amount of solvent . the solvent is evaporated to yield a solid mass which is ground , sized and optionally formulated into an appropriate delivery system . other techniques , known in the art , such as for example fusion or fusion - evaporation , may also be used . the delivery system of the present invention results in increased solubility and bioavailability , and improved dissolution rate of the lipid - regulating agent . if the solvent evaporation technique is used , suitable solvents include , for example , lower alkyl alcohols such as methanol , ethanol , or any other pharmaceutically - acceptable organic solvent in which the lipid - regulating agent and the polymers have appreciable solubility . suitable hydrophilic , amorphous polymers include , for example , polyvinylpyrrolidone ( pvp ), hydroxypropylmethylcellulose ( hpmc ), or other pharmaceutically - acceptable hydrophilic , amorphous polymers such as for example , eudragits ®. other pharmaceutically - acceptable excipients may be added to the formulation prior to forming the desired final product . suitable excipients include , for example , lactose , starch , magnesium stearate , or other pharmaceutically - acceptable fillers , diluents , lubricants , disintegrants , etc ., that might be needed to prepare a capsule or tablet . the resulting composition comprising the lipid - regulating agent may be dosed directly for oral administration , diluted into an appropriate vehicle for oral administration , filled into capsules , or made into tablets for oral administration , or delivered by some other means obvious to those skilled in the art . the said composition can be used to improve the oral bioavailability and solubility of said lipid - regulating agent . the invention will be understood more clearly from the following non - limiting representative examples : a mixture ( 3 g ) of fenofibrate and pvp ( pf 17 ) in a ratio of 15 : 85 was dissolved in 4 . 5 ml of ethanol . the ethanol was evaporated under vacuum at 85 ° c . the resulting dry solid was then ground and sized through a 60 - 100 mesh screen . 446 . 7 mg of the granular formulation ( containing 67 mg fenofibrate ) was filled into individual capsules . a mixture ( 3 g ) of statin and pvp ( pf 17 ) in a ratio of 15 : 85 is dissolved in sufficient ethanol . the ethanol is evaporated under vacuum at 85 ° c . the resulting dry solid is then ground and sized through a 60 - 100 mesh screen . the solid is then filled in capsules to obtain the desired unit dose . capsules prepared by the process described in example 1 , and from a commercial fenofibrate composition , lipanthyl 67m ( groupe fournier ) ( reference ), were administered to a group of dogs at a dose of 67 mg fenofibrate / dog . the plasma concentrations of fenofibric acid were determined by hplc . concentrations were normalized to a 6 . 7 mg / kg dose in each dog . fig1 presents the resulting data in graph form . the results provided as mean ± sd , n = 6 , were as follows :
the present invention is directed to a solid formulation comprising the lipid - regulating agent dispersed in a hydrophilic , amorphous polymer in which said lipid - regulating agent is present as a meta - stable , amorphous phase .